UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Tracy Staton Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times ...

UPDATED: Hedge fund’s attack on troubled Zafgen draws blood

John Carroll These days, while success and victory still have 1,000 fathers, failure and defeat have its outspoken champions as well. FierceBiotech News

Shire’s Lialda, Gattex are hedge funder’s latest patent targets

Tracy Staton Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent ...

Hedge funder’s first assault on iffy drug patents? Acorda’s MS med Ampyra

Tracy Staton Last month, Texas hedge fund manager Kyle Bass said he had pharma and its "questionable" patents in his sights. Now, he's made his first move–and he's ...

Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

Emily Wasserman As companies, regulators and advocacy groups lobby to bring certain branded products off-patent, a new voice is joining the chorus. U.S. hedge fund manager Kyle Bass, ...

Wearing biotech hat, hedge fund vet Shkreli shakes the gate at Transcept

Ryan McBride Martin Shkreli's biotech outfit Retrophin has proposed a buyout of struggling Transcept Pharmaceuticals for $ 4 per share, but the management of Point Richmond, CA-based ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS